Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD

This is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety and efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in patients with Schimke immuno-osseous dysplasia. It is planned to enroll 20 participants in this trial.

Inclusion criteria

• 1. Diagnosed as SIOD and was in stage 5 of chronic kidney disease
• 2. Having allogeneic HSCT indications, at least suitable donors (relatives) for haploidentical allogeneic transplantation and kidneys from stem cell transplantation donors;
• 3. serum total bilirubin ≤ 1.5 times the upper limit of normal, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were both ≤ 3 times the upper limit of the normal range.
• 4. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;
• 5. There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%；
• 6. Estimated survival time ≥ 3 months;
• 7. ECOG performance status 0 to 1;
• 8. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;
• 9. Those who voluntarily participated in this trial and provided informed consent;

Exclusion criteria

• 1. Allergic to pretreatment measures
• 2. received any containing ATG/ALG such IST、alemtuzumab、high-dose cyclophosphamide (≥ 45mg/kg/day) , received CsA treatment within 6 months, or used thrombopoietin receptor (tpo-r) agonists in the past;
• 3. Patients with the history of epilepsy or other CNS disease;
• 4. Patients with prolonged QT interval time or severe heart disease;
• 5. Previous recipients of allogeneic hematopoietic stem cell transplantation or organ transplantation
• 6. People infected with HIV, active hepatitis B or hepatitis C virus, and patients with active infection who are not cured;
• 7. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
• 8. Patients with malignant tumor;
• 9. People with other genetic diseases；
• 10. After receiving CD7 car-t treatment, patients who were unable to accept subsequent kidney transplantation due to severe infection or poor amplification of car-t in vivo.
• 11. Any situation that researchers believe may increase the risk to the subjects or interfere with the trial results.